查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
臨床試驗中的區塊鏈市場－2023年至2028年預測
市場調查報告書
商品編碼
1410138

臨床試驗中的區塊鏈市場－2023年至2028年預測

Blockchain In Clinical Trials Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2021年區塊鏈臨床試驗市場規模預計為103,054,000美元

在醫療保健和製藥業，臨床試驗的區塊鏈市場正在成為遊戲規則的改變者。這種新穎的策略有望透過利用區塊鏈技術的去中心化和不可逆性來提高臨床試驗過程的開放性、安全性和效率。區塊鏈提供了一種分散式帳本技術，允許相關人員之間即時交換和檢驗臨床實驗資料，同時保持資料完整性。區塊鏈透過簡化資料管理、身份驗證和同意程序來減少資料操縱的威脅並確保監管合規性。這項技術增強了參與者的信心，縮短了試驗時間，降低了成本，並徹底改變了臨床試驗。隨著對課責和資料的需求不斷成長，臨床試驗中的區塊鏈市場有望徹底改變藥物研究並推動患者照護領域的突破。

提高資料透明度和完整性將推動臨床試驗中區塊鏈市場的成長

提高資料透明度和完整性是臨床試驗市場區塊鏈的關鍵成長動力。區塊鏈的去中心化和不可變的帳本​​架構使臨床試驗資料可見、可追溯、防篡改。研究人員、監管機構和患者都可以安全地即時存取和檢驗資料，從而促進信任和協作。這種透明度的提高有助於及早檢測和解決資料異常，確保測試結果的準確性和可靠性。此外，消除集中式資料孤島可以降低資料篡改和未授權存取的風險，從而提高資料完整性。隨著臨床試驗對強大資料管理和信任的要求不斷提高，區塊鏈技術的普及程度也不斷提高，推動市場成長。

簡化臨床試驗區塊鏈市場中的資料管理和共用

臨床試驗中區塊鏈市場的一個顯著成長因素是簡化資料管理和共用。區塊鏈的分散式帳本技術以安全且高效的方式簡化了各個相關人員之間的資料儲存、組織和共用。向研究人員、醫療保健提供者和監管機構提供臨床實驗進展、患者資料和結果的即時更新，從而實現無縫協作和決策。資料可以即時上傳、更新和審核，消除了手動記錄保存和不必要的資料輸入。區塊鏈技術透過打破資料孤島和維護資料、縮短臨床試驗期限並提高整體藥物開發和患者照護效率來改善整體資料管理流程。

詐欺和資料篡改的減少將推動臨床試驗中的區塊鏈市場規模。

減少詐欺和資料篡改是臨床試驗市場區塊鏈的關鍵成長要素。區塊鏈的去中心化和不可變性確保資料一旦記錄就無法編輯或刪除，從而消除了資料篡改或未授權存取的風險。區塊鏈上的每筆交易都安全地連接到先前的條目，從而形成透明且審核的資料追蹤。資料品質和開放性的提高減少了詐欺並保護敏感的患者資訊。區塊鏈技術可以透過培養患者、研究人員和監管機構等相關人員之間的信任，減少資料操縱的可能性並確保臨床試驗結果的準確性，從而幫助推動臨床試驗的這種轉變，從而導致技術的廣泛採用。

北美是臨床試驗區塊鏈市場的市場領導者

北美是臨床試驗區塊鏈的市場領導者。該地區的受歡迎程度可能與其完善的醫療保健基礎設施、對研發的重視以及大量重要製藥和生物技術公司的存在有關。此外，北美在採用區塊鏈等最尖端科技並將其整合到醫療保健系統方面處於領先地位。該地區有利的法律規範以及研究機構和技術供應商之間的合作夥伴關係推動了區塊鏈在臨床試驗中的使用。然而，臨床試驗市場區塊鏈頂級區域的市場動態可能正在改變。

增加臨床試驗中區塊鏈市場的病患招募與參與度

病患招募和參與是臨床試驗市場區塊鏈的關鍵成長動力。區塊鏈技術使個人能夠更好地控制自己的健康資料，並允許他們直接參與臨床研究。患者可以安全地與研究人員交換健康資訊並同意參加試驗，從而改善招募。此外，區塊鏈的開放和去中心化性質可以確保患者能夠清楚地看到他們的資料將如何使用，從而提高患者的信任，從而保障資料保護。透過加強患者參與和賦權，臨床試驗現在可以接觸到更廣泛的不同參與者，從而產生更具代表性和穩健的研究結果，並最終治療方法，並促進治療方法的改進。

公司產品

  • 區塊鏈基礎設施解決方案英特爾為區塊鏈網路的開發和部署提供硬體和軟體解決方案。這些基礎設施解決方案旨在提高臨床試驗區塊鏈系統的效能、安全性和可擴展性。
  • AccenturemyConcerto(TM)：由Accenture開發的 myConcerto(TM) 是一個基於區塊鏈的平台，旨在提高臨床試驗的效率和透明度。該技術使相關人員能夠安全、即時地共用資料，從而增強協作和決策。
  • IBM 臨床開發： IBM 臨床開發平台結合了區塊鏈技術來加速臨床試驗資料管理，由 IBM Watson Health 提供。該平台實現了包括研究人員、贊助商和監管機構在內的相關人員之間安全、透明的資料交換。
  • Medidata Rave Clinical Cloud： Medidata Rave Clinical Cloud 是一個完整的雲端基礎的平台，利用區塊鏈技術進行資料管理和安全。該平台能夠安全、防篡改地收集、處理和儲存臨床試驗資料。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表

第2章調查方法

  • 調查資料
  • 資訊來源
  • 研究設計

第3章執行摘要

  • 研究亮點

第4章市場動態

  • 市場促進因素
  • 市場抑制因素
  • 波特五力分析
    • 供應商的議價能力
    • 買方議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 業內競爭對手之間的對抗關係
  • 產業價值鏈分析

第5章臨床試驗中的區塊鏈市場：按區塊鏈類型

  • 介紹
  • 公共區塊鏈
  • 私有區塊鏈
  • 聯盟鏈
  • 混合區塊鏈

第6章臨床試驗中的區塊鏈市場：依應用分類

  • 介紹
  • 病患資料管理
  • 供應鏈管理
  • 臨床資料交換與共用
  • 臨床試驗記錄管理
  • 管理知情同意
  • 藥品可追溯性和真實性
  • 其他

第7章臨床試驗中的區塊鏈市場：按最終用戶分類

  • 介紹
  • 製藥公司
  • 委託研究組織（CROS）
  • 研究機構和學術中心
  • 醫療服務提供方
  • 其他
  • 臨床試驗市場中的區塊鏈：按地區
  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 台灣
    • 其他

第8章競爭環境及分析

  • 主要企業及策略分析
  • 新興企業和市場盈利
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第9章 公司簡介

  • IBM CORPORATION
  • MICROSOFT CORPORATION
  • ORACLE CORPORATION
  • ACCENTURE PLC
  • MEDIDATA SOLUTIONS, INC.（NOW PART OF DASSAULT SYSTEMES）
  • CONSENSYS HEALTH
  • PFIZER INC.
  • ENCRYPGEN, INC.
  • BITFURY GROUP LIMITED
  • GUARDTIME AS
簡介目錄
Product Code: KSI061615808

The blockchain in clinical trials market was valued at US$103.054 million in 2021.

In the healthcare and pharmaceutical industries, the blockchain in clinical trials market has emerged as a transformational force. This novel strategy promises to improve openness, security, and efficiency in the clinical trial process by leveraging blockchain technology's decentralised and irreversible nature. Blockchain provides a distributed ledger technology that allows for the real-time exchange and verification of trial data across stakeholders while maintaining data integrity. Blockchain reduces data manipulation threats and assures regulatory compliance by streamlining data management, authentication, and consent procedures. This technology increases participant trust, shortens trial times, and lowers costs, revolutionising how clinical trials are done. As the desire for more accountability and data integrity develops, blockchain in clinical trials market is poised to revolutionise drug research and push patient care breakthroughs.

Improved Data Transparency and Integrity Enhances the Blockchain in Clinical Trials Market Growth.

Improved data transparency and integrity are critical growth drivers in the blockchain in clinical trials market. Clinical trial data becomes visible, traceable, and tamper-proof thanks to blockchain's decentralised and immutable ledger architecture. Researchers, regulators, and patients may all safely access and verify data in real-time, encouraging confidence and collaboration. This increased transparency aids in the early detection and resolution of data anomalies, assuring the accuracy and dependability of trial outcomes. Furthermore, removing centralised data silos reduces the danger of data modification and unauthorised access, hence improving data integrity. As the requirement for robust data management and trust in clinical trials grows, so does the popularity of blockchain technology, driving market growth.

Streamlined Data Management and Sharing in Blockchain in Clinical Trials Market.

A prominent growth element in the blockchain in clinical trials market is streamlined data management and sharing. The distributed ledger technology of blockchain streamlines data storage, organisation, and sharing among various stakeholders in a safe and efficient manner. Real-time updates on trial progress, patient data, and outcomes are available to researchers, healthcare providers, and regulators, allowing for seamless cooperation and decision-making. Data may be uploaded, updated, and audited in real-time, eliminating the need for manual record-keeping and unnecessary data entry. Blockchain technology improves the whole data management process by removing data silos and maintaining data integrity, shortening clinical trial deadlines and improving overall drug development and patient care efficiency.

Reduction in Fraud and Data Manipulation Boosts the Blockchain in Clinical Trials Market Size.

Reduced fraud and data tampering are critical growth drivers in the blockchain in clinical trials market. The decentralised and unchangeable nature of blockchain assures that data cannot be edited or erased once recorded, removing the danger of data tampering and unauthorised access. Each transaction on the blockchain is securely connected to prior entries, resulting in a data trail that is transparent and auditable. This improved data quality and openness discourages fraudulent practises and safeguards sensitive patient information. Blockchain technology fosters trust among stakeholders, including patients, researchers, and regulatory authorities, by reducing the possibility of data manipulation and ensuring the accuracy of clinical trial results, resulting in widespread adoption of this transformative technology in clinical trials.

North America is the Market Leader in the Blockchain in Clinical Trials Market.

North America was regarded as the market leader in the blockchain in clinical trials market. The popularity of this region may be linked to its well-established healthcare infrastructure, a strong emphasis on R&D, and the presence of numerous important pharmaceutical and biotechnology businesses. Furthermore, North America has been in the forefront of adopting and integrating cutting-edge technology such as blockchain into healthcare systems. The region's favourable regulatory framework, as well as alliances between research institutes and technology suppliers, have advanced the use of blockchain in clinical trials. However, market dynamics may have changed, in the top region in the blockchain in clinical trials market.

Increased Patient Recruitment and Engagement in Blockchain in Clinical Trials Market.

Patient recruitment and engagement are important growth drivers in the blockchain in clinical trials market. Blockchain technology gives individuals more control over their health data and allows them to participate directly in clinical studies. Patients may safely exchange their health information with researchers and consent to participate in trials, which improves recruitment. Furthermore, the open and decentralised nature of blockchain increases patient confidence by offering a clear knowledge of how their data will be utilised and protecting data protection. Clinical trials can access a broader pool of varied participants with enhanced patient participation and empowerment, resulting in more representative and robust research outputs, eventually promoting improvements in medical treatments and cures.

Key Developments:

  • In May 2023, Medidata, a Dassault Systemes business, is expanding its Patient Insights Programme through a collaboration with Canary Advisors, a consulting firm specialising in patient-centred medication and device development. The Patient Insights Programme at Medidata incorporates a patient-centred approach into the design and development of clinical trial protocols and technology. Medidata creates unique workshops to assist the development of patient-facing solutions to enhance clinical trial experiences, accelerate clinical trial delivery times, and bring treatments to market more quickly.
  • In June 2023, IBM announced a $4.6 billion purchase deal with Vista Equity Partners for Apptio Inc., a pioneer in financial and operational IT management and optimization (FinOps) software. Apptio's purchase will accelerate IBM's IT automation capabilities and empower company executives to achieve greater business value from technology investments.
  • In July 2023, Bira 91, an Indian premium beer brand with operations in 24 countries, is engaging with Accenture on an enterprise reinvention programme to boost growth, enhance business agility, and accelerate innovation. Accenture will assist Bira 91 in designing and deploying a digital core, which incorporates data, artificial intelligence, and machine learning, using SAP S/4HANA to allow a holistic reinvention of its organisation through the convergence of different technological platforms, as part of its transformation plan. The scalable technological platform, which is cloud-based, will boost data visibility and accessibility across the organisation, assisting in decision-making and increasing productivity.

Company Products:

  • Blockchain Infrastructure Solutions: Intel supplied hardware and software solutions for the development and deployment of blockchain networks. These infrastructure solutions sought to improve the performance, security, and scalability of clinical trial blockchain systems.
  • Accenture myConcerto™: Accenture developed myConcerto™, a blockchain-enabled platform meant to improve clinical trial efficiency and transparency. The technology enabled stakeholders to share data in a safe and real-time manner, increasing cooperation and decision-making.
  • IBM Clinical Development: The IBM Clinical Development platform, which combined blockchain technology to accelerate clinical trial data administration, was delivered by IBM Watson Health. The platform enabled secure and transparent data exchange among many parties, including researchers, sponsors, and regulatory bodies.
  • Medidata Rave Clinical Cloud: Medidata Rave Clinical Cloud was a complete cloud-based platform that utilised blockchain technology for data management and security. The platform permitted the safe and tamper-proof gathering, processing, and storage of clinical trial data.

Segmentation:

By Type Of Blockchain

  • Public Blockchain
  • Private Blockchain
  • Consortium Blockchain
  • Hybrid Blockchain

By Application

  • Patient Data Management
  • Supply Chain Management
  • Clinical Data Exchange And Sharing
  • Clinical Trial Recordkeeping
  • Informed Consent Management
  • Drug Traceability And Authenticity
  • Others

By End-User

  • Pharmaceutical Companies
  • Contract Research Organizations (Cros)
  • Research Institutes And Academic Centers
  • Healthcare Providers
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Sources
  • 2.3. Research Design

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. BLOCKCHAIN IN CLINICAL TRIALS MARKET, BY TYPE OF BLOCKCHAIN

  • 5.1. Introduction
  • 5.2. PUBLIC BLOCKCHAIN
  • 5.3. PRIVATE BLOCKCHAIN
  • 5.4. CONSORTIUM BLOCKCHAIN
  • 5.5. HYBRID BLOCKCHAIN

6. BLOCKCHAIN IN CLINICAL TRIALS MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. PATIENT DATA MANAGEMENT
  • 6.3. SUPPLY CHAIN MANAGEMENT
  • 6.4. CLINICAL DATA EXCHANGE AND SHARING
  • 6.5. CLINICAL TRIAL RECORDKEEPING
  • 6.6. INFORMED CONSENT MANAGEMENT
  • 6.7. DRUG TRACEABILITY AND AUTHENTICITY
  • 6.8. OTHERS

7. BLOCKCHAIN IN CLINICAL TRIALS MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. PHARMACEUTICAL COMPANIES
  • 7.3. CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 7.4. RESEARCH INSTITUTES AND ACADEMIC CENTERS
  • 7.5. HEALTHCARE PROVIDERS
  • 7.6. OTHERS
  • 7.7. BLOCKCHAIN IN CLINICAL TRIALS MARKET, BY GEOGRAPHY
  • 7.8. Introduction
  • 7.9. North America
    • 7.9.1. United States
    • 7.9.2. Canada
    • 7.9.3. Mexico
  • 7.10. South America
    • 7.10.1. Brazil
    • 7.10.2. Argentina
    • 7.10.3. Others
  • 7.11. Europe
    • 7.11.1. United Kingdom
    • 7.11.2. Germany
    • 7.11.3. France
    • 7.11.4. Italy
    • 7.11.5. Spain
    • 7.11.6. Others
  • 7.12. Middle East and Africa
    • 7.12.1. Saudi Arabia
    • 7.12.2. UAE
    • 7.12.3. Others
  • 7.13. Asia Pacific
    • 7.13.1. Japan
    • 7.13.2. China
    • 7.13.3. India
    • 7.13.4. South Korea
    • 7.13.5. Indonesia
    • 7.13.6. Taiwan
    • 7.13.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. IBM CORPORATION
  • 9.2. MICROSOFT CORPORATION
  • 9.3. ORACLE CORPORATION
  • 9.4. ACCENTURE PLC
  • 9.5. MEDIDATA SOLUTIONS, INC. (NOW PART OF DASSAULT SYSTEMES)
  • 9.6. CONSENSYS HEALTH
  • 9.7. PFIZER INC.
  • 9.8. ENCRYPGEN, INC.
  • 9.9. BITFURY GROUP LIMITED
  • 9.10. GUARDTIME AS